{"nctId":"NCT00688064","briefTitle":"Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris","startDateStruct":{"date":"2008-08"},"conditions":["Severe Acne Vulgaris"],"count":459,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Adapalene BPO Gel associated with Doxycyline Hyclate"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Vehicle Gel associated with Doxycycline Hyclate"]}],"interventions":[{"name":"Adapalene BPO Gel associated with Doxycyline Hyclate","otherNames":["Adapalene-BPO gel + Doxycycline"]},{"name":"Vehicle Gel associated with Doxycycline Hyclate","otherNames":["Vehicle gel + Doxycycline"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female Subjects of any race, aged 12 to 35 years inclusive\n* Subjects with severe facial acne (global severity score of 4)\n* Subjects with a minimum of 20 inflammatory lesions (papules and pustules) on the face, excluding the nose\n* Subjects with a minimum of 30 and a maximum of 120 non-inflammatory lesions (open comedones and closed comedones) on the face, excluding the nose\n\nExclusion Criteria:\n\n* Subjects with more than 3 nodules or cysts on the face,\n* Subjects with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.)","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"35 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Total Lesion Counts at Week 12.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-64","spread":null},{"groupId":"OG001","value":"-41","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Inflammatory Lesion Counts at Week 12.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-72","spread":null},{"groupId":"OG001","value":"-48","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-inflammatory Lesion Counts at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-61","spread":null},{"groupId":"OG001","value":"-40","spread":null}]}]}]},{"type":"SECONDARY","title":"Success Rate on the Investigator's Global Assessment","description":"Percentage of subjects graded \"Clear\" or \"Almost Clear\" on 6-point IGA scale(0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe and 5=very severe)at week 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.5","spread":null},{"groupId":"OG001","value":"8.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Subjects With Adverse Events","description":"Percent of subjects with Adverse Events all along the study (up to 12 weeks follow-up period)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"26.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":232},"commonTop":["nasopharyngitis","nausea","vomiting","upper respiratory tract infection","dyspepsia"]}}}